Valproic acid autoinduction: a case-based review

Bergemann N, Kress KR, Abu-Tair F, Frick A, Kopitz J. Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol. 2006;26(4):432–4.

PubMed  Article  Google Scholar 

Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35(7):1032–41.

CAS  PubMed  Article  Google Scholar 

Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45(1):89–93.

CAS  PubMed  Article  Google Scholar 

de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: pharmacological issues and further understanding. Rev Psiquiatr Salud Ment. 2015;8(3):167–88.

PubMed  Article  Google Scholar 

de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: a summary of the current state for clinicians. Rev Psiquiatr Salud Ment. 2015b;8(2):97–115.

PubMed  Article  Google Scholar 

de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007;81(1):42–9.

PubMed  Article  CAS  Google Scholar 

de Maat MM, van Leeuwen HJ, Edelbroek PM. High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy. Ann Pharmacother. 2011;45(3):e18.

PubMed  Article  Google Scholar 

Diaz FJ, Eap CB, Ansermot N, Crettol S, Spina E, de Leon J. Can valproic acid be an inducer of clozapine metabolism? Pharmacopsychiatry. 2014;47(3):89–96.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, et al. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet. 2015;54(3):305–17.

CAS  PubMed  Article  Google Scholar 

Dutta S, Faught E, Limdi NA. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy. J Clin Pharm Ther. 2007;32(4):365–71.

CAS  PubMed  Article  Google Scholar 

Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiat. 1994;36(7):487–8.

CAS  PubMed  Article  Google Scholar 

Fisher JE, Nau H, Loscher W. Alterations in the renal excretion of valproate and its metabolites after chronic treatment. Epilepsia. 1991;32(1):146–50.

CAS  PubMed  Article  Google Scholar 

Franco V, Perucca E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin Drug Metab Toxicol. 2015;11(8):1269–79.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4):236–41.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Guo Y, Hu C, He X, Qiu F, Zhao L. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet. 2012;27(5):536–42.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Haslemo T, Olsen K, Lunde H, Molden E. Valproic acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking. Ther Drug Monit. 2012;34(5):512–7.

CAS  PubMed  Article  Google Scholar 

Hermida J, Tutor JC. A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients. J Pharmacol Sci. 2005;97(4):489–93.

CAS  PubMed  Article  Google Scholar 

Hooper WD, Franklin ME, Glue P, Banfield CR, Radwanski E, McLaughlin DB, et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. Epilepsia. 1996;37(1):91–7.

CAS  PubMed  Article  Google Scholar 

Hung CC, Ho JL, Chang WL, Tai JJ, Hsieh TJ, Hsieh YW, et al. Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics. 2011;12(8):1107–17.

CAS  PubMed  Article  Google Scholar 

Jackson J, McCollum B, Ognibene J, Diaz FJ, de Leon J. Three patients needing high doses of valproic acid to get therapeutic concentrations. Case Rep Psychiatry. 2015;2015:542862.

PubMed  PubMed Central  Google Scholar 

Jiang D, Bai X, Zhang Q, Lu W, Wang Y, Li L, et al. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol. 2009;65(12):1187–93.

CAS  PubMed  Article  Google Scholar 

Kallen B. Valproic acid is known to cause hypospadias in man but does not reduce anogenital distance or causes hypospadias in rats. Basic Clin Pharmacol Toxicol. 2004;94(1):51–4.

PubMed  Article  Google Scholar 

Kim SC, Kim MG. A meta-analysis of the influence of UGT1A6 genetic polymorphisms on valproic acid pharmacokinetics. Int J Clin Pharmacol Ther. 2019;57:144–51.

CAS  PubMed  Article  Google Scholar 

Kodama Y, Kodama H, Kuranari M, Tsutsumi K, Ono S, Yukawa E, et al. Gender- or age-related binding characteristics of valproic acid to serum proteins in adult patients with epilepsy. Eur J Pharm Biopharm. 2001;52(1):57–63.

CAS  PubMed  Article  Google Scholar 

Lai ML, Huang JD. Dual effect of valproic acid on the pharmacokinetics of phenytoin. Biopharm Drug Dispos. 1993;14(4):365–70.

CAS  PubMed  Article  Google Scholar 

Lampen A, Siehler S, Ellerbeck U, Gottlicher M, Nau H. New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). Toxicol Appl Pharmacol. 1999;160(3):238–49.

CAS  PubMed  Article  Google Scholar 

Lana F, Marti-Bonany J, Fuster J, de Leon J. Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto-induction metabolism. Actas Esp Psiquiatr. 2016a;44(4):136–44.

PubMed  Google Scholar 

Lana F, Marti-Bonany J, de Leon J. Ibuprofen may increase pharmacological action of valproate by displacing it from plasma proteins: a case report. Am J Psychiatry. 2016b;173(9):941–2.

PubMed  Article  Google Scholar 

Li Q, Lugt CB, Looareesuwan S, Krudsood S, Wilairatana P, Vannaphan S, et al. Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria. Am J Trop Med Hyg. 2004;71(6):723–31.

CAS  PubMed  Article  Google Scholar 

Longo LP, Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am J Psychiatry. 1995;152(4):650.

CAS  PubMed  Google Scholar 

Luci S, Geissler S, Konig B, Koch A, Stangl GI, Hirche F, et al. PPARalpha agonists up-regulate organic cation transporters in rat liver cells. Biochem Biophys Res Commun. 2006;350(3):704–8.

CAS  PubMed  Article  Google Scholar 

Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, et al. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine. Clin Pharmacol Ther. 2018;104(6):1191–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

McLaughlin DB, Eadie MJ, Parker-Scott SL, Addison RS, Henderson RD, Hooper WD, et al. Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient. Epilepsy Res. 2000;41(3):259–68.

CAS  PubMed  Article  Google Scholar 

Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018;84(5):816–34.

PubMed  PubMed Central  Article  Google Scholar 

Morris RG, Black AB, Lam E, Westley IS. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit. 2000;22:656–60.

CAS  PubMed  Article  Google Scholar 

Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473–81.

CAS  PubMed  Article  Google Scholar 

Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–76.

CAS  PubMed  Article  Google Scholar 

Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, Crema A. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther. 1980;28(6):779–89.

CAS  PubMed  Article  Google Scholar 

Perucca E, Berlowitz D, Birnbaum A, Cloyd JC, Garrard J, Hanlon JT, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res. 2006;68(Suppl 1):S49-63.

CAS  PubMed  Article  Google Scholar 

Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. J Clin Pharm Ther. 2005;30(5):417–21.

留言 (0)

沒有登入
gif